6990:HKEXSichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Analysis

The stock is trading at HK$514, comfortably above the 20‑day SMA of 428 but still below the 200‑day SMA of 445, indicating a short‑term pull‑back within a longer‑term bearish framework. Momentum signals are mixed: the RSI sits at 68 (near overbought), the MACD histogram is strongly positive (14.06) and the MACD line is well above the signal line, yet the overall trend is classified as bearish and price volatility is elevated at 64% over the past 30 days. Valuation metrics are extreme – a forward P/E of 153 versus an industry average of 26, a P/B of 21.3 and a price‑to‑sales of 58 – suggesting the market has priced in substantial future growth. Recent material news adds a catalyst: the company disclosed Phase III OptiTROP‑Lung05 results for its sac‑TMT ADC at ASCO, and presented first‑in‑human data on the B7‑H3 ADC SKB500, both of which could unlock significant revenue streams if successful.
Fundamentally, the firm remains loss‑making with negative operating and profit margins, a high debt‑to‑equity ratio of 1.8, and negative cash flows, but it holds a strong cash position (HK$4.47 bn) and a modest beta of 0.46, implying limited systematic risk. The combination of a high‑priced, high‑volatility stock, a pipeline‑driven upside narrative, and ongoing regulatory uncertainties frames a nuanced investment case that leans toward growth‑oriented buying on a medium‑to‑long horizon while remaining cautious in the near term.